| SOAR 0.2875 69.12% | HUBC 0.4702 80.08% | AIM 0.8985 120.33% | SOXS 6.17 -2.53% | SPCE 7.54 22.01% | ZCMD 0.0763 -54.31% | TZA 4.355 0.58% | NVDA 222.149 5.21% | NOK 16.41 10.58% | SBEV 0.1691 -1.34% | TGHL 1.525 338.47% | BITO 9.7323 -2.87% | ANY 4.211 121.63% | OPTU 1.135 72.44% | INTC 110.585 -3.57% | ABTS 2.82 184.36% | DEVS 0.3898 29.93% | AMC 1.965 13.91% | HKIT 6.04 313.70% | SOFI 18.7 2.63% | BBAI 5.355 6.25% | HCWC 0.3886 16.73% | GNTA 1.785 73.30% | F 17.01 -2.47% | WOK 0.1024 8.47% | ONDS 13.415 1.48% | ABVE 0.11 -81.25% | CXAI 0.2143 3.28% | NIO 5.9693 6.59% | TSLL 14.775 -7.19% | RGTI 25.775 0.92% | DVLT 0.5773 15.46% | NVD 4.42 -9.80% | AAL 14.37 -1.84% | ACHR 6.8701 0.88% | GDC 0.1235 12.27% | HPE 45.64 6.04% | IBIT 40.49 -2.74% | SQQQ 37.37 -1.86% | TQQQ 86.16 1.89% | PATH 12.925 10.28% | XLE 57.26 1.72% | PLTR 162.524 3.82% | PLUG 4.0099 1.52% | FFAI 0.3932 8.14% | CRWV 125.64 14.71% | IREN 65.6906 3.38% | BURU 0.182 2.54% | QTEX 3.2013 4.28% | JZ 2.09 187.09%

Centene Corporation (NYSE:CNC) Soars on Strong Q1 Earnings and Raised Profit Outlook

Centene Corporation (NYSE:CNC) is a major health insurance company that focuses on providing government-sponsored healthcare plans. Its main business involves offering Medicaid and Medicare programs. As a managed-care company, Centene works to control healthcare costs for its members while maintaining the quality of medical services provided.

Following strong quarterly results, analyst Sarah James from Raymond James sets a new price target for Centene at $60.00. With the stock trading at $49.57, this new target represents a potential increase of approximately 21.04%. This optimism is supported by the company's recent financial performance and improved cost management.

The company reports strong first-quarter results, with net earnings rising to $1.54 billion. Its adjusted earnings per share (EPS), which shows profit per share after certain adjustments, reaches $3.37. This figure significantly beats analyst expectations of $2.23 per share, driven by successful efforts to manage medical costs.

Total revenue increases by 7.1% to $49.94 billion, also surpassing Wall Street's forecast. This revenue growth is supported by its core government programs. Revenue from its Medicaid segment grows by 6% to $23.60 billion, while its Medicare segment sees a substantial 18% climb to $10.30 billion.

As highlighted by Reuters, Centene raises its 2026 adjusted profit forecast due to better control over medical costs. The company now projects a full-year adjusted diluted EPS of greater than $3.40. This updated guidance suggests confidence in its ability to manage expenses and improve profitability moving forward.

Published on: April 29, 2026